{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:19:03Z","timestamp":1788448743679,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jaad.2021.06.873","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T02:20:23Z","timestamp":1625278823000},"page":"414-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Janus kinase inhibitors in dermatology: Part II. A\u00a0comprehensive review"],"prefix":"10.1016","volume":"86","author":[{"given":"Stephanie","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.873_bib2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.873_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2021.06.873_bib4","series-title":"Tofacitinib. Package insert","author":"XELJANZ","year":"2018"},{"issue":"7","key":"10.1016\/j.jaad.2021.06.873_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2016.03.008","article-title":"Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies","volume":"15","author":"Gilhar","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.873_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.jaad.2021.06.873_bib8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2021.06.873_bib9","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","article-title":"Successful treatment of alopecia totalis with Ruxolitinib in a preadolescent patient","volume":"6","author":"Peterson","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jaad.2021.06.873_bib11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"15","key":"10.1016\/j.jaad.2021.06.873_bib12","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral Ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.06.873_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","volume":"34","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.873_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.873_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.873_bib19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor Ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.873_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2021.06.873_bib22","first-page":"1","article-title":"Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","author":"Phan","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/pde.14159","article-title":"Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child","volume":"37","author":"Olamiju","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"10244","key":"10.1016\/j.jaad.2021.06.873_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2021.06.873_bib25","doi-asserted-by":"crossref","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under Ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"26","key":"10.1016\/j.jaad.2021.06.873_bib27","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.873_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of multiorgan sarcoidosis with tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.873_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.yexmp.2014.04.006","article-title":"Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis","volume":"96","author":"Christophi","year":"2014","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"10.1016\/j.jaad.2021.06.873_bib30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2019.10.016","article-title":"Treatment of granuloma annulare with tofacitinib 2% ointment","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2021.06.873_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdcr.2019.11.016","article-title":"Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"9894","key":"10.1016\/j.jaad.2021.06.873_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"issue":"10143","key":"10.1016\/j.jaad.2021.06.873_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.jaad.2021.06.873_bib35","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2021.06.873_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib37","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jaad.2020.04.098","article-title":"Reply: potential role of Janus kinase inhibitors in COVID-19","volume":"83","author":"Napolitano","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.06.873_bib38","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2020.04.097","article-title":"Reply: calm before the storm: understanding the role of Janus kinase inhibitors in COVID-19","volume":"83","author":"Peterson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.06.873_bib39","author":"American Academy of Dermatology Association"},{"issue":"8","key":"10.1016\/j.jaad.2021.06.873_bib40","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/art.41301","article-title":"American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1","volume":"72","author":"Mikuls","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2021.06.873_bib41","author":"COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases"},{"key":"10.1016\/j.jaad.2021.06.873_bib43","series-title":"COVID-19 Vaccine Information","article-title":"COVID-19 Vaccine administration guidance","author":"Tomecki","year":"2021"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221020223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221020223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:39Z","timestamp":1759273299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221020223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0190962221020223"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.06.873","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors in dermatology: Part II. A\u00a0comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.06.873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}